Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Free Cash Flow (2021 - 2025)

Historic Free Cash Flow for Prime Medicine (PRME) over the last 5 years, with Q3 2025 value amounting to -$35.3 million.

  • Prime Medicine's Free Cash Flow fell 2978.04% to -$35.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$115.1 million, marking a year-over-year increase of 3952.46%. This contributed to the annual value of -$130.2 million for FY2024, which is 2525.44% up from last year.
  • According to the latest figures from Q3 2025, Prime Medicine's Free Cash Flow is -$35.3 million, which was down 2978.04% from -$43.0 million recorded in Q2 2025.
  • Prime Medicine's 5-year Free Cash Flow high stood at $14.5 million for Q4 2024, and its period low was -$70.0 million during Q1 2024.
  • Its 5-year average for Free Cash Flow is -$37.2 million, with a median of -$42.1 million in 2023.
  • Its Free Cash Flow has fluctuated over the past 5 years, first crashed by 16182.47% in 2022, then surged by 13162.52% in 2024.
  • Prime Medicine's Free Cash Flow (Quarter) stood at -$13.6 million in 2021, then plummeted by 161.82% to -$35.5 million in 2022, then dropped by 28.65% to -$45.7 million in 2023, then surged by 131.63% to $14.5 million in 2024, then tumbled by 344.13% to -$35.3 million in 2025.
  • Its last three reported values are -$35.3 million in Q3 2025, -$43.0 million for Q2 2025, and -$51.3 million during Q1 2025.